501692-44-0 Usage
Uses
Used in Pharmaceutical Industry:
1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-(R)-α-[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl)carbamoylmethoxy-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine is used as a potential therapeutic agent for its possible biological activity and pharmacological relevance. 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-(R)-α-[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl)carbamoylmethoxy-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine's structure suggests that it may have applications in medicine, warranting further research to determine its specific properties and potential uses in treating various conditions.
Used in Chemical Research:
In the field of chemical research, 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-(R)-α-[N-((S)-1-carboxypropyl)carbamoyl]-4-hydroxybenzyl)carbamoylmethoxy-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine serves as a subject of study for understanding its synthesis, properties, and potential interactions with biological systems. This research can contribute to the development of new drugs and therapeutic strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 501692-44-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,1,6,9 and 2 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 501692-44:
(8*5)+(7*0)+(6*1)+(5*6)+(4*9)+(3*2)+(2*4)+(1*4)=130
130 % 10 = 0
So 501692-44-0 is a valid CAS Registry Number.
501692-44-0Relevant academic research and scientific papers
BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA
-
Paragraph 0169, (2018/01/13)
The present invention relates to compounds of formula (I) wherein Rv, R1, R2, Rx, Ry, M, Rz, v, R3, R4, R5 and R6 are as defined within; pharmace
Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
-
, (2013/05/09)
Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI)
